Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Rezlidhia (olutasidenib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novo Nordisk, Rigel

Drug class:

IDH1 inhibitor

Related drugs:

IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1
IDH1 R132	Acute Myelogenous Leukemia	IDH1 R132	Acute Myelogenous Leukemia	olutasidenib Sensitive: C2 – Inclusion Criteria olutasidenib Sensitive : C2	olutasidenib Sensitive: C2 – Inclusion Criteria olutasidenib Sensitive : C2
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3
IDH1 R132G	Acute Myelogenous Leukemia	IDH1 R132G	Acute Myelogenous Leukemia	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3
IDH1 R132C	Acute Myelogenous Leukemia	IDH1 R132C	Acute Myelogenous Leukemia	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3
IDH1 R132L	Acute Myelogenous Leukemia	IDH1 R132L	Acute Myelogenous Leukemia	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3
IDH1 R132S	Acute Myelogenous Leukemia	IDH1 R132S	Acute Myelogenous Leukemia	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3	olutasidenib Sensitive: C3 – Early Trials olutasidenib Sensitive : C3